Contact Us
Synthetic Biology Inspired Medicines
We design and engineer microbial strains rationally to develop innovative bacterial vaccines.
Discover more
Delonix is a world leading biotech company dedicated to developing next generation genetically engineered bacterial vaccines.
Founded by experts in synthetic biology and vaccinology, Delonix aims to transform the development of bacterial vaccines through multiple platforms powered by synthetic biology.
Platforms We Established
BioDVax
platform
BioDesigned bacterial factory for Vaccine. BioDVax engineers polysaccharide, toxin and other components of pathogens, aiming to improve subunit vaccine immunogenicity and optimize manufacturing process with higher yield and more consistent production.
OMV Plus
platform
Proprietary genetically engineered OMV technology platform, which enables robust OMV vaccine candidate generation. Validated by the development of a potential BIC group B meningococcal vaccine.
ProBVax
platform
Programming Bacterial cells for Vaccine. ProBVax leverages rational design and novel bacterial immune checkpoint MOA to develop next generation live-attenuated vaccine, enabling fast optimization of safety and efficacy.
01
Synthetic Biology
Technology
  • Complete toolkits for non-model microbe engineering
  • Data-driven rational design
  • High throughput & automation
02
PathX
Technology
  • PathX: Pathogenic bacteria gene editing
  • Fast, precise and versatile pathogen editing
  • Seemless editing of 16+ pathogens
What's happening about us?
  • Delonix Bioworks Wins Boehringer Ingelheim’s Innovation Prize in 2020
    Oct 10, 2021
  • Delonix Bioworks Closes $14 Million Series Seed Financingto Accelerate the Development of its Innovative Synthetic Vaccines
    Oct 10, 2021
  • $14 Million Series Seed Financingto Accelerate the Development of its Innovative Synthetic Vaccines
    Oct 10, 2021
  • Delonix Bioworks Wins Boehringer Ingelheim’s Innovation Prize in 2020
    Oct 10, 2021
  • Delonix Bioworks Wins Boehringer Ingelheim’s Innovation Prize in 2020
    Oct 10, 2021